Newsletter registration


Immunophenotyping in multiple myeloma: Patients without minimal residual disease live longer
Successful Re-Accreditation of MLL

The prognostic significance of minimal residual disease (MRD) in patients with multiple myeloma has been examined in numerous studies and is the subject of much controversial discussion. Existing data has to date been extremely heterogeneous with regard to patient collectives, therapies, number of cases, and the methodology via which MRD was detected. However, since the presentation of the meta-analysis by Munshi et al. (JAMA 2017), it can be considered as proven that MRD negativity after first-line therapy is one of the strongest surrogate markers for prolonged overall survival.

Read more

Since 2009, MLL has been accredited according to the international standards DIN EN ISO 15189 "Medical laboratories - Requirements for quality and competence" and DIN EN ISO/IEC 17025 "General requirements for the competence of testing and calibration laboratories" by the Deutsche Akkreditierungsstelle (DAkkS). In April this year, MLL was once again audited by DAkkS. Its existing accreditations were successfully upheld and expanded with new analyses.

Read more


07.11.2019 - 08.11.2019
MLL Academy - Next-Generation Sequencing

Molecular genetics plays an important role in the diagnostic, prognostic and therapeutic evaluation of hematological disorders and will continue to gain importance in the future. Next-Generation Sequencing (NGS) is an essential method in a modern molecular diagnostic portfolio. This is why the MLL Munich Leukemia Laboratory offers a specialized MLL Academy focused on NGS. The course will take place from November 7th until November 8th 2019.

Read more


Kristina von Sayn-Wittgenstein

MLL Münchner Leukämielabor GmbH
Max-Lebsche-Platz 31
81377 München

T: +49 (0)89 99017-506

Getting here